MGF
MGF / PEG-MGF (Mechano Growth Factor)
A splice variant of the IGF-1 gene expressed in muscle in response to mechanical stress. Activates muscle satellite cells at the site of damage.
MGF is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
Mechano Growth Factor (MGF) is produced by the body as an alternative splice variant of the IGF-1 gene specifically in response to mechanical stimulation (i.e., exercise or muscle damage). Unlike systemic IGF-1, which circulates throughout the body, MGF acts locally at the site of muscle damage.
In research, two forms are studied: native MGF (very short plasma half-life of approximately 5 minutes) and PEG-MGF (pegylated version with extended half-life of 24–72 hours). The latter allows systemic delivery that mimics the local signal more practically.
What research shows
- Activates muscle satellite cells — dormant stem cells that fuse with damaged muscle fibers to enable repair and growth
- Local activity at muscle damage sites — mechanistically distinct from systemic IGF-1
- Muscle fiber protection and recovery in animal models
- PEG-MGF extends half-life sufficiently for practical research use
- Potentially additive with IGF-1 LR3 through complementary mechanisms
What remains unknown
- Optimal dosing and timing relative to training in humans
- Long-term safety profile
- Whether systemic PEG-MGF delivery adequately replicates localized MGF signaling
Administration basics
Common use cases
Muscle repair, satellite cell activation, recovery from training. Typically used post-workout.
Half-life
~5 minutes (MGF) / 24–72 hours (PEG-MGF).
Administration
Intramuscular injection into the target muscle. Post-workout timing is standard.
Source this compound
Looking for MGF?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Animal research has used 200–400mcg per injection
- PEG-MGF community protocols commonly report 200mcg injected 2–3 times per week
Administration routes studied
Typical protocol duration
Community protocols typically report 4–6 week cycles.
Common stacking protocols
- MGF + IGF-1 LR3 — MGF first to activate satellite cells, then IGF-1 LR3 for proliferation
- MGF + GH peptides (Ipamorelin/CJC-1295) — combined in performance protocols
Contraindications & combinations to avoid
- Active cancer or cancer history — MGF acts through the IGF-1 receptor pathway
- Should not be combined with insulin without medical supervision
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with MGF and what to avoid.
Track your MGF protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the MGF page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.